PCRX
Pacira BioSciences, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
138.84
PEG
1.30
P/B
1.39
P/S
1.34
EV/EBITDA
10.45
DCF Value
$676.05
FCF Yield
14.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
77.4%
Operating Margin
2.8%
Net Margin
1.0%
ROE
0.9%
ROA
0.8%
ROIC
0.7%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $196.9M | $1.6M | $0.04 |
| FY 2025 | $726.4M | $7.0M | $0.16 |
| Q3 2025 | $179.5M | $5.4M | $0.12 |
| Q2 2025 | $181.1M | $-4.8M | $-0.11 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.20
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.